It is pretty interesting reading about what the judge said in the hearing about the injunction filed by Sanofi and also how the FDA responded. Both sounded very like they bode well for MNTA. I also liked reading what the Medco had to say about what enoxoparin means to patient costs and to Medco. And yet the mythical "efficient market" keeps driving MNTA down. I wish to thank the "efficient market" for its gift, so I doubled my shares of MNTA today at $16.26. That is pretty easy to do since I didn't have that much (yet).
I started injecting the Lovenox 40mg/0.4ml Solution, 0.4ml Syringe once/daily on July 1; my husband and I are trying to get pregnant, and I need to be on the anticoagulants because I have three genetic predispositions for clotting. Coumadin is what I have been taking, but it can harm a growing fetus. When I started the Lovenox, my *copay* through my insurance was $110 for a two-week supply, or $2860/year (25% of full price, which would make the full-price medication $11,440/year). Now that the generic is available, a 3-MONTH supply is roughly $450, or $1800/year (full price of generic is then $7200/year, or approximately 37% less). Hope that sheds some light on this - it’s still expensive, but we’re so glad there’s a generic available - trying to have a baby is expensive enough!
Market Data 
Markets 
AI
